{"version":"1.0","provider_name":"Basel Area Business &amp; Innovation","provider_url":"https:\/\/test.baselarea.swiss\/de\/","author_name":"martin","author_url":"https:\/\/test.baselarea.swiss\/de\/author\/martin\/","title":"Boehringer Ingelheim \u00fcbernimmt T3 Pharma","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"vZYYqX0wQ5\"><a href=\"https:\/\/test.baselarea.swiss\/de\/blog-post\/boehringer-ingelheim-ubernimmt-t3-pharma\/\">Boehringer Ingelheim \u00fcbernimmt T3 Pharma<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/test.baselarea.swiss\/de\/blog-post\/boehringer-ingelheim-ubernimmt-t3-pharma\/embed\/#?secret=vZYYqX0wQ5\" width=\"600\" height=\"338\" title=\"&#171;Boehringer Ingelheim \u00fcbernimmt T3 Pharma&#187; &#8212; Basel Area Business &amp; Innovation\" data-secret=\"vZYYqX0wQ5\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/test.baselarea.swiss\/\/wp-content\/uploads\/2023\/01\/Simon_Ittig_T3-Pharma.jpg","thumbnail_width":800,"thumbnail_height":600,"description":"Boehringer Ingelheim hat T3 Pharma mit Sitz im Switzerland Innovation Park Basel Area f\u00fcr bis zu 450 Millionen Franken erworben. Der Spezialist f\u00fcr bakterielle Krebstherapie wird weiter in der Region Basel t\u00e4tig sein."}